Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Team gives drug dropouts a second chance

By Drug Discovery Trends Editor | May 7, 2012

A cross-disciplinary team of researchers at the University of Maryland
has designed a molecular container that can hold drug molecules and increase
their solubility, in one case up to nearly 3000 times. Their discovery opens
the possibility of rehabilitating drug candidates that were insufficiently
soluble. It also offers an opportunity to improve successful drugs that could
be made even better with better solubility.

The team’s innovative findings were recently published in Nature Chemistry, in which the authors
note that “the solubility characteristics of 40% to 70% percent of new
drug candidates are so poor that they cannot be formulated on their own, so new
methods for increasing drug solubility are highly prized.“

The Maryland
scientists where able to increase the solubility of ten insoluble drugs by
between 23 and 2,750 times, by forming container-drug complexes. They also show
that their containers have low toxicity in human cell line and mice studies,
and that the molecular containers can be built from inexpensive and readily
available reagents.

“We already are working with drug companies to help them solubilize
their interesting drug candidates and hope to get them interested in licensing
our technology,” says co-leader Volker Briken, an associate professor in
the department of cell biology and molecular genetics and also a scientist in
the Maryland Pathogen Research Institute.

The team, led by Briken and UMD Chemistry and Biochemistry Professor Lyle
Isaacs, created their “new class of general-purpose solubilizing
agents” based on a type of compound called cucurbit[n]urils—or CB[n].
These are ‘macrocyclic’ molecules made up of units of bicyclic glycoluril C4H4N4O2
monomers. The n in CB[n] refers to the number of repeat units in the macrocycle.

Many previous attempts have been made to capture drug molecules within these
and other synthetic cages and capsules to increase drugs’ solubility, but with
limited success.

Issacs and Briken say that next their team would like to increase the
variety of novel acyclic CBs in order to be able to solubilize a maximal number
of small chemical drug candidates, and also would like to generate CBs that can
be specifically targeted—for example to cancer cells.

University of Maryland


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE